Glycine by enteral route does not improve major clinical outcomes in severe COVID-19: a randomized clinical pilot trial

Abstract There is a worrying scarcity of drug options for patients with severe COVID-19. Glycine possesses anti-inflammatory, cytoprotective, endothelium-protective, and platelet-antiaggregant properties, so its use in these patients seems promising. In this open label, controlled clinical trial, in...

Full description

Bibliographic Details

Published in:	Scientific Reports
Main Authors:	Mario H. Vargas, Jaime Chávez, Rosangela Del-Razo-Rodríguez, Carolina Muñoz-Perea, Karina Julieta Romo-Domínguez, Renata Báez-Saldaña, Uriel Rumbo-Nava, Selene Guerrero-Zúñiga
Format:	Article
Language:	English
Published:	Nature Portfolio 2024-05-01
Online Access:	https://doi.org/10.1038/s41598-024-62321-7